Product Reports Resources Pricing Login Book a demo

Zhejiang Taimei Medical Technology

Biotech & Life Sciences · Huangpu, China · Founded 2013 · IPO 2024

Zhejiang Taimei Medical Technology Co., Ltd. operates as a digital solutions provider for the life science industry, with a strategic focus on the pharmaceutical and medical device sectors in China. Founded by Zhao Lu in June 2013, the company aims to enhance the research and development (R&D) and commercialization processes for its clients. Zhao Lu, who serves as the company's chairman, is the largest shareholder. Taimei Technology's business model is centered on providing cloud-based, software-as-a-service (SaaS) products, eliminating the need for clients to install and maintain software on-premise. The company generates revenue through the sale of these self-developed SaaS products and by offering related professional services in the fields of clinical research, pharmacovigilance, and pharmaceutical marketing. Its clientele includes pharmaceutical companies, contract research organizations (CROs), and research institutes. By March 2024, Taimei had served over 1,400 pharmaceutical firms and CROs, including 21 of the top 25 global pharmaceutical companies. The company's core offering is its TrialOS platform, a digital collaboration hub designed to connect key industry stakeholders such as pharmaceutical companies, hospitals, service providers, regulatory bodies, and patients. This platform facilitates data exchange and process cooperation by leveraging artificial intelligence, big data, and mobile internet technologies. In addition to TrialOS, the company offers PharmaOS, a digital marketing platform that integrates omnichannel marketing systems to provide data-driven solutions for sales management and customer targeting. Taimei also provides over 40 distinct software products and digital services, including solutions for clinical trial management, data collection and analysis, and pharmacovigilance. These offerings support the entire drug product lifecycle, from R&D to post-market activities. Keywords: life sciences digital platform, clinical research software, pharmacovigilance solutions, pharmaceutical marketing, SaaS for pharma, TrialOS platform, drug development technology, clinical trial management, medical device R&D solutions, contract research organization services, digital health China, eClinical solutions, Zhao Lu, data-driven healthcare, healthcare IT, pharmaceutical commercialization, medical data management, cloud-based healthcare software, regulatory compliance software, PharmaOS

Valuation $100–500M
Revenue $50–100M
Headcount 100–500
Total funding $500M–1B
Power Law Unicorn$1–10B valuation tier Colt$25–100M revenue

Investors

14 investors on Zhejiang Taimei Medical Technology's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage
Matrix Partners China
NLVC
Cowin Venture
Series B+ 11 investors entered at this stage
Genesis Capital
SB China Capital
SAIF Partners
Zheshang Venture Capital
Ivy Capital
5Y Capital
Tiger Global
Tencent
GL Ventures
YunFeng Capital
Hillhouse Capital

Global footprint

Where Zhejiang Taimei Medical Technology has talent and traffic

Workforce by country
3 countries with
team presence
🇨🇳 China93%
🇺🇸 United States5.6%
🇸🇬 Singapore1.4%
3 countries shown

Talent graph

The shape of Zhejiang Taimei Medical Technology's talent

Dealroom maps Zhejiang Taimei Medical Technology's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

3 team members profilednamed & role-tagged by Dealroom
178 employeestotal headcount
2 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Zhejiang Taimei Medical Technology's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$12M patent portfolio · 230 active families

Estimated portfolio value
$12M
5.7% of market cap · 98.6× larger than top peer Benchling ($122k)
230 active patent families
Where Zhejiang Taimei Medical Technology innovates Clinical testsComputer engineeringComputer equipmentData miningData processing

Where Zhejiang Taimei Medical Technology concentrates vs peers

Each axis is a top-10 topic across Zhejiang Taimei Medical Technology and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Zhejiang Taimei Medical Technology

An AI-synthesized read of the highest-engagement posts about Zhejiang Taimei Medical Technology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Zhejiang Taimei Medical Technology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles